Opna Bio is targeting key regulators to advance the treatment of cancer. OPN-6602, a best-in-class EP300 inhibitor, is currently in clinical development for treatment of patients with multiple myeloma. OPN-2853, a differentiated BET inhibitor, is being developed for the treatment of myelofibrosis.
EXPLORE OUR PIPELINE
Opna Bio is dedicated to discovering and developing novel treatments for cancer patients everywhere.
We are currently validating our approach of competitive safety and efficacy through differentiated PK with our epigenetic inhibitors, OPN-6602 and OPN-2853. Both compounds are currently in early-stage clinical development in patients with hematologic malignancies.
Explore our Clinical TrialsOPN-6602 is Currently in a Phase 1 Clinical Trial for Relapsed/Refractory Multiple Myeloma
Preclinical Data with OPN-6602 in Multiple Myeloma Show 100% Tumor Regression in Combination Treatment Studies